STIC Search Report
EIC 3700

STIC Database Tracking Number: 200008

TO: Paul Prebilic
Location: RND 6c03
Art Unit: 3738
Monday, October 02, 2006

Case Serial Number: 10/770403

From: Kristine Sasala
Location: EIC 3700
Randolph 8A18-C
Phone: (571)272-3337

kristine.sasala@uspto.gov

Search Notes

Attached is the completed search. I did an extensive search on the requested topic in a number of bibliographic and full-text databases as well as on the Internet. I also searched the inventors in both patent and non-patent literature and have included those results. The things I thought were significant are marked with colored flags. Please be sure to look over all the results as there may be other items of interest. I have attached the search strategies used for the searches performed.

I hope you find this search helpful. If you have a moment, please fill out the attached STIC Feedback Form. And, if there is anything I can do to refine or revise this search, please let me know.

Sincerely,
Kris Sasala (ASRC)

Solomon, Terrance 20008

From: PAUL PREBILIC [paul.prebilic@uspto.gov]
Sent: Tuesday, August 29, 2006 7:08 AM
To: STIC-EIC3700
Subject: Database Search Request, Serial Number: 10770403

Requester:
PAUL PREBILIC (P/3738)
Art Unit:
GROUP ART UNIT 3738
Employee Number:
65450
Office Location:
RND 06C03
Phone Number:
(571)272-4758
Mailbox Number:



Case serial number:
10770403
Class / Subclass(es):
623/23.64
Earliest Priority Filing Date:
February 4, 2004
Format preferred for results:
E-mail
Search Topic Information:
Please search for a method of treating morbid obesity in a patient by reducing gastic blood flow, duodenal blood flow, mesenteric blood flow, jejunal blood flow, ileal blood flow or combinations thereof by inserting a blood flow reducing device inside or outside an artery that carries blood to the small intestine.
Special Instructions and Other Comments:

```
SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R) 1950-2006/Sep 28
         (c) format only 2006 Dialog
  File  73:EMBASE 1974-2006/Sep 28
         (c) 2006 Elsevier B.V.
  File   5:Biosis Previews(R) 1969-2006/Sep W4
         (c) 2006 The Thomson Corporation
  File  34:SciSearch(R) Cited Ref Sci 1990-2006/Sep W4
         (c) 2006 The Thomson Corp
  File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 2006 The Thomson Corp

      Set  Items  Description
      ---  -----  -----------
Cost is in DialUnits
?
Terminal set to DLINK
? ds

Set     Items   Description
S1       5267   AU=(MURPHY T? OR MURPHY TP?)
S2       2689   ENDOGRAFT?
S3          0   S1 AND S2
S4    5683868   VASCULAR? OR RADIOLOG? OR IMAGING OR ENDOVASCULAR?
S5        706   S1 AND S4
S6     188884   (VASCULAR? OR ENDOVASCULAR?) AND (RADIOLOG? OR IMAGING)
S7         31   S1 AND S6
S8         29   RD  (unique items)
```

8/7/10 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE

10959651 EMBASE No: 2001004585
Technical aspects of aortoiliac interventions
Murphy T.P.
Dr. T.P. Murphy, Department of Diagnostic Imaging, Brown University School of Medicine, Rhode Island Hospital, 593 Eddy St., Providence, RI 02903 United States
Techniques in Vascular and Interventional Radiology (TECH. VASC. INTERVENT. RADIOL.) (United States) 2000, 3/4 (189-194)
CODEN: TVIRF ISSN: 1089-2516
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 5

Just as preparation is integral to the success of any job, so is having the proper tools. It is fruitless to attempt an interventional procedure without the proper equipment. It is impossible to predict reliably the equipment necessary to complete an intervention for every patient; a broad range of catheters and guide wires must be available. If traversal of a chronically occluded artery, or any maneuver for that matter, becomes frustrating, another tool is probably needed for the job. It is simply a matter of figuring out which one, often through trial and error. Familiarity with the physical properties associated with various angioplasty balloons and stents, in addition to catheters and guide wires, is a prerequisite of expert **vascular** intervention. There are many options to chose from, but usually there is one best option. Knowledge of pharmacology is required for procedural success. There are many pitfalls associated with stent deployment, which are discussed. (C) 2000 by W.B. Saunders Company.

8/7/11 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE

10959650 EMBASE No: 2001004584
Aortoiliac interventions: Getting started
Murphy T.P.
Dr. T.P. Murphy, Department of Diagnostic Imaging, Brown University School of Medicine, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903 United States
Techniques in Vascular and Interventional Radiology (TECH. VASC. INTERVENT. RADIOL.) (United States) 2000, 3/4 (186-188)
CODEN: TVIRF ISSN: 1089-2516
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Preparation is the key to the successful completion of any job. Before performing any procedure, the operator should be intimately familiar with the patient's complaint, the natural history of the disease process, and the risks and benefits of any potential interventions relative to the patient's problem. There are several considerations regarding diagnostic arteriography that implicate subsequent interventions. In general, the common femoral artery is the optimal access route for arteriography and

intervention. Occasionally, ipsilateral femoral access facilitates iliac artery revascularization, and other times contralateral access is better. Bilateral femoral access is often required. Accessing a common femoral artery without a pulse is often necessary and can usually be achieved without much difficulty. If the external iliac artery is occluded ipsilateral to the accessed femoral artery, then specialized equipment is required to permit the exchange of the access needle and traversal of the occluded lilac artery. (C) 2000 by W.B. Saunders Company.

8/7/14 (Item 9 from file: 73)
DIALOG(R)File 73:EMBASE

07772383 EMBASE No: 1999255084
Endovascular **graft-related iliac artery infection**
Sheeran S.R.; Gestring M.L.; **Murphy T.P.** ; Slaiby J.M.
Dr. T.P. Murphy, Div. of Vasc./Interventional Radiol., Rhode Island Hospital, Brown University School of Medicine, 593 Eddy St., Providence, RI 02903 United States
Journal of Vascular and Interventional Radiology (J. VASC. INTERVENT. RADIOL.) (United States) 1999, 10/7 (877-882)
CODEN: JVIRE ISSN: 1051-0443
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 21

8/7/21 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0013121474 BIOSIS NO.: 200100293313
Traumatic thoracic aortic rupture: Treatment with endovascular **graft in the acute setting**
AUTHOR: Ahn Sun Ho; Cutry Anthony; **Murphy Timothy P** (Reprint); Slaiby Jeffrey M
AUTHOR ADDRESS: Department of Radiology, 593 Eddy Street, Providence, RI, 02903, USA**USA
JOURNAL: Journal of Trauma Injury Infection and Critical Care 50 (5): p 949-951 May, 2001 2001
MEDIUM: print
ISSN: 1079-6061
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: English

```
Set     Items   Description
S1   35230980   METHOD? ? OR PROCEDURE? ? OR PROCESS OR TECHNIQUE? ?  OR D-
            EVICE? ?
S2   17134465   (METHOD? ? OR PROCEDURE? ? OR PROCESS OR TECHNIQUE? ?  OR -
            DEVICE? ?)/TI,DE
S3   17333300   PRODUC??? OR INDUC??? OR CREAT???
S4    3610606   (INHIBIT? OR REDUC? OR DECREAS? OR DIMINISH? OR LESSEN? OR
            RESTRICT? OR RETARD OR HINDER? OR LIMIT?)/TI
S5    2601376   (BLOOD? OR ARTER? OR VASCULA? OR ENDOVASCULAR)/TI
S6    2415413   GASTRIC OR GASTRODUOD? OR DUODEN? OR MESENTER? OR  JEJUNO?
            OR JEJUN?? OR ILE?? OR ILEO? OR INTESTIN?
S7      37350   S5(3N)S6
S8      68198   S2(3N)S4
S9      39387   S4(2N)S5
S10    108896   S2(3N)S3
S11         0   S7(5N)S8(5N)S9
S12         0   S7 AND S8 AND S9
S13    630839   S1(3N)S3
S14     49496   S4(3N)S5
S15        15   S13(S)S14
S16         7   RD  (unique items)
S17         0   (S8(S)S14) AND S7
S18    2184  S4(5N)S6(5N)S5
S19     348  S18 AND S1
S20       3  S18(10N)S1
S21       3  RD  (unique items)
? s s18(s)s1
S22       3  S18(S)S1
S23      30  S18 AND OBES????
S24      12  RD  (unique items)
```

```
SYSTEM:OS  - DIALOG OneSearch
  File 155:MEDLINE(R) 1950-2006/Sep 28
         (c) format only 2006 Dialog
  File   5:Biosis Previews(R) 1969-2006/Sep W4
         (c) 2006 The Thomson Corporation
  File  34:SciSearch(R) Cited Ref Sci 1990-2006/Sep W4
         (c) 2006 The Thomson Corp
  File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 2006 The Thomson Corp
  File  73:EMBASE 1974-2006/Sep 29
         (c) 2006 Elsevier B.V.
  File  74:Int.Pharm.Abs 1970-2006/Aug B1
         (c) 2006 The Thomson Corporation
  File   2:INSPEC 1898-2006/Sep W3
         (c) 2006 Institution of Electrical Engineers
  File   6:NTIS 1964-2006/Sep W3
         (c) 2006 NTIS, Intl Cpyrght All Rights Res
  File   8:Ei Compendex(R) 1970-2006/Sep W3
         (c) 2006 Elsevier Eng.  Info. Inc.
  File  35:Dissertation Abs Online 1861-2006/Sep
         (c) 2006 ProQuest Info&Learning
  File  65:Inside Conferences 1993-2006/Sep 28
         (c) 2006 BLDSC all rts. reserv.
  File  94:JICST-EPlus 1985-2006/Jun W3
         (c)2006 Japan Science and Tech Corp(JST)
  File  98:General Sci Abs 1984-2006/Sep
         (c) 2006 The HW Wilson Co.
  File  99:Wilson Appl. Sci & Tech Abs 1983-2006/Jul
         (c) 2006 The HW Wilson Co.
  File 144:Pascal 1973-2006/Sep W1
         (c) 2006 INIST/CNRS
  File  23:CSA Technology Research Database 1963-2006/Sep
         (c) 2006 CSA.
```

21/5/1 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

19311272 PMID: 15634399

[The clinical study on application of using a novel blockade technique **for** gastric **cancer to** decrease blood **-borne metastasis of cancer cells]**

Huang Guang-Jian; Zhang Qun-Hua; Zhang Yan-Ling; Gan Jun; Chen Yu-Ming; Guan Ming; Ni Quan-Xing

Department of Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.

Zhonghua wai ke za zhi Chinese journal of surgery (China) Nov 22 2004, 42 (22) p1345-8, ISSN 0529-5815--Print Journal Code: 0153611

Publishing Model Print

Document type: Journal Article

Languages: CHINESE

Main Citation Owner: NLM

Record type: In Process

Subfile: INDEX MEDICUS

OBJECTIVE: To evaluate the effect of a novel blockade technique for gastric cancer on blood-borne metastasis of gastric cancer cells to portal vein. METHODS: Twenty-three cases of gastric cancer were divided into routine operation group (8 cases intraoperatively without blockade technique) and blockade group (15 cases with blockade technique). Blood samples from portal vein pre- and intraoperatively, as well as gastroepiploic vein limited within the blockade area were obtained to detect CK19 mRNA expression by using RT-PCR technique. RESULTS: Before the dissection of gastric lesion, the overall positive rate of CK19 mRNA expression in portal vein blood is 34.7% (9/23), including 37.5% (3/8) in routine operation group and 33.3% (5/15) in blockade group. While the course of tumor resection, those positive rates were 87.5% (7/8) in routine operation group and 6.7% (1/15) in blockade group respectively ($P < 0.05$). CK19 mRNA expression in the right gastroepiploic venous blood limited within the blocking area was all positive in 15 cases of blockade group. CONCLUSION: This blockade technique can be used effectively to block the intraoperative spread of gastric cance

24/5/8 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0002311642 BIOSIS NO.: 197815029129
CARDIO VASCULAR **EFFECTS OF WEIGHT** REDUCTION **AFTER** INTESTINAL **SHUNT OPERATION FOR** OBESITY
AUTHOR: FREYSCHUSS U; BACKMAN L; HALLBERG D; MELCHER A
JOURNAL: British Heart Journal 40 (4): p462 1978
ISSN: 0007-0769
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: Unspecified
DESCRIPTORS: ABSTRACT JEJUNO ILEOSTOMY
DESCRIPTORS:
MAJOR CONCEPTS: Cardiovascular Medicine--Human Medicine, Medical Sciences ; Digestive System--Ingestion and Assimilation; Nutrition
BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia
COMMON TAXONOMIC TERMS: Animals; Chordates; Humans; Mammals; Primates; Vertebrates
CONCEPT CODES:
11105 Anatomy and Histology - Surgery
12002 Physiology - General
12512 Pathology - Therapy
13203 Nutrition - Malnutrition and obesity
14001 Digestive system - General and methods
14506 Cardiovascular system - Heart pathology
14508 Cardiovascular system - Blood vessel pathology
BIOSYSTEMATIC CODES:
86215 Hominidae

```
Set     Items   Description
S1   10607043   (BLOOD? OR ARTER? OR VASCULA? OR ENDOVASCULAR)/TI,DE
S2    4020151   CIRCULAT???
S3    2438687   GASTRIC OR GASTRODUOD? OR DUODEN? OR MESENTER? OR  JEJUNO?
            OR JEJUN?? OR ILE?? OR ILEO? OR INTESTIN? OR SPLANCHN?
S4   23972020   INHIBIT? OR REDUC? OR DECREAS? OR DIMINISH? OR LESSEN? OR -
          RESTRICT? OR RETARD OR HINDER? OR LIMIT? OR CONSTRICT???
S5       2469   BLOODFLOW?
S6    6300276   FLOW OR SUPPLY??? OR SUPPLI???
S7     134779   S1:S2(5N)S3
S8     356057   S4(5N)S5:S6
S9        346   S8(S)THERAPEUTIC()USE
S10         4   S9 AND S7
S11      1508   S7(S)S8
S12     64522   S4(S)THERAPEUTIC()USE
S13         4   S11 AND S12
S14   2438687   S3/BS
S15    625492   ISCHEMIA/TU
S16     37159   S14 AND S15
S17     25936   S14(S)S15
S18   1062559   S3/TI
S19     14566   S18 AND S17
S20       512   S5/TI
S21   3635185   S4/TI
S22      6125   S4 AND S19
S23        13   (S1 AND S2 AND S3 AND S4 AND (S5:S6))/TI
S24         8   RD  (unique items)
File 155:MEDLINE(R) 1950-2006/Sep 28
         (c) format only 2006 Dialog
File   5:Biosis Previews(R) 1969-2006/Sep W4
         (c) 2006 The Thomson Corporation
File  34:SciSearch(R) Cited Ref Sci 1990-2006/Sep W4
         (c) 2006 The Thomson Corp
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
         (c) 2006 The Thomson Corp
File  73:EMBASE 1974-2006/Sep 29
         (c) 2006 Elsevier B.V.
File  74:Int.Pharm.Abs 1970-2006/Aug B1
         (c) 2006 The Thomson Corporation
File   2:INSPEC 1898-2006/Sep W3
         (c) 2006 Institution of Electrical Engineers
File   6:NTIS 1964-2006/Sep W3
         (c) 2006 NTIS, Intl Cpyrght All Rights Res
File   8:Ei Compendex(R) 1970-2006/Sep W3
         (c) 2006 Elsevier Eng.  Info. Inc.
File  35:Dissertation Abs Online 1861-2006/Sep
         (c) 2006 ProQuest Info&Learning
File  65:Inside Conferences 1993-2006/Sep 29
         (c) 2006 BLDSC all rts. reserv.
File  94:JICST-EPlus 1985-2006/Jun W3
         (c)2006 Japan Science and Tech Corp(JST)
File  98:General Sci Abs 1984-2006/Sep
         (c) 2006 The HW Wilson Co.
File  99:Wilson Appl. Sci & Tech Abs 1983-2006/Jul
         (c) 2006 The HW Wilson Co.
File 144:Pascal 1973-2006/Sep W1
         (c) 2006 INIST/CNRS
File  23:CSA Technology Research Database 1963-2006/Sep
         (c) 2006 CSA.
```

24/5/6 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0001898793 BIOSIS NO.: 197661064932
CONTINUOUS BLOOD FLOW **AS A MANIFESTATION OF** REDUCED CIRCULATION **IN** INTESTINAL **INTRA MURAL VESSELS**
AUTHOR: SIGAL Z M
JOURNAL: Patologicheskaya Fiziologiya i Eksperimental'naya Terapiya (4): p 74-77 1975
ISSN: 0031-2991
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: Unspecified
DESCRIPTORS: DOG BLOODLESS METHOD LIGATION
DESCRIPTORS:
MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Blood and Lymphatics--Transport and Circulation; Cardiovascular System--Transport and Circulation; Digestive System--Ingestion and Assimilation
BIOSYSTEMATIC NAMES: Canidae--Carnivora, Mammalia, Vertebrata, Chordata, Animalia
COMMON TAXONOMIC TERMS: Animals; Carnivores; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman Mammals; Vertebrates
CONCEPT CODES:
10502 Biophysics - General
11104 Anatomy and Histology - Experimental anatomy
12100 Movement
14001 Digestive system - General and methods
14004 Digestive system - Physiology and biochemistry
14006 Digestive system - Pathology
14501 Cardiovascular system - General and methods
14504 Cardiovascular system - Physiology and biochemistry
14508 Cardiovascular system - Blood vessel pathology
15002 Blood - Blood and lymph studies
BIOSYSTEMATIC CODES:
85765 Canidae

24/5/7 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

0000177003 BIOSIS NO.: 196905080155
CIRCULATORY **RESPONSES TO ACUTE** REDUCTION **OF SUPERIOR** MESENTERIC ARTERIAL FLOW
AUTHOR: BOLEY S J; TREIBER W; WINSLOW P R; GLIEDMAN M L; VEITH F J
JOURNAL: Physiologist 12 (3): p180 1969
ISSN: 0031-9376
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: Unspecified
DESCRIPTORS: ABSTRACT DOG
DESCRIPTORS:
MAJOR CONCEPTS: Cardiovascular System--Transport and Circulation
BIOSYSTEMATIC NAMES: Canidae--Carnivora, Mammalia, Vertebrata, Chordata, Animalia
COMMON TAXONOMIC TERMS: Animals; Carnivores; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman Mammals; Vertebrates
CONCEPT CODES:
14504 Cardiovascular system - Physiology and biochemistry
14508 Cardiovascular system - Blood vessel pathology

BIOSYSTEMATIC CODES:
85765 Canidae

24/5/2 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

04030355 PMID: 1187231
[Continuous blood flow **as a manifestation of** reduced blood circulation **in the intramural vessels of the** intestine]
Nepreryvnyi krovotok kak proiavlenie redutsirovannogo krovoobrashcheniia v intramural'nykh sosudakh kishki
Sigal Z M
Patologicheskaia fiziologiia i eksperimental'naia terapiia (USSR) Jul-Aug 1975, (4) p74-7, ISSN 0031-2991--Print Journal Code: 0376421
Publishing Model Print
Document type: Journal Article ; English Abstract
Languages: RUSSIAN
Main Citation Owner: NLM
Record type: MEDLINE; Completed
Subfile: INDEX MEDICUS
Descriptors: *Intestines--blood supply--BS; *Regional Blood Flow; Animals ; Blood Pressure; Dogs; English Abstract; Ligation
Record Date Created: 19760123
Record Date Completed: 19760123

24/5/3 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

01241317 PMID: 13683150
Distribution of splanchnic **and peripheral** blood flow **during acute** reduction **in** circulatory **rate: studies during total body perfusion.**
ANDERSEN M N; HAMBRAEUS G; ALFANO G A; SCHENK W G
Annals of surgery (Not Available) Apr 1961, 153 p477-82, ISSN 0003-4932--Print Journal Code: 0372354
Publishing Model Print
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: OLDMEDLINE; Completed
Subfile: OLDMEDLINE
Descriptors: *Blood Circulation--physiology--PH; *Heart, Artificial
Identifiers: *BLOOD CIRCULATION/physiology; *HEART, MECHANICAL
Record Date Created: 19611201
Record Date Completed: 19981101

```
Set     Items   Description
S1     497349   BLOOD? OR ARTER? OR VASCULA? OR ENDOVASCULAR OR CIRCULATORY
S2      71066   GASTRIC OR GASTRODUOD? OR DUODEN? OR MESENTER? OR  JEJUNO?
             OR JEJUN?? OR ILE?? OR ILEO? OR INTESTIN? OR SPLANCHN?
S3        221   BLOODFLOW?
S4    6112295   FLOW OR SUPPLY??? OR SUPPLI???
S5    7889757   INHIBIT? OR REDUC? OR DECREAS? OR DIMINISH? OR LESSEN? OR -
            RESTRICT? OR RETARD OR HINDER? OR LIMIT? OR CONSTRICT???
S6   18192574   PRODUC??? OR INDUC??? OR CREAT???
S7        886   S1(2N)S2
S8     118053   S5(2N)(S1OR S3 OR S4)
S9      37316   S1(5N)S5
S10        13   S7(S)S8(S)S9
S11        13   RD  (unique items)
S12      1613   S1(5N)S2
S13    209088   S5(5N)(S1OR S3 OR S4)
S14        59   S12(S)S13(S)S9
S15        46   RD  (unique items)
File  16:Gale Group PROMT(R) 1990-2006/Sep 28
         (c) 2006 The Gale Group
File 160:Gale Group PROMT(R) 1972-1989
         (c) 1999 The Gale Group
File 148:Gale Group Trade & Industry DB 1976-2006/Sep 29
         (c)2006 The Gale Group
File 621:Gale Group New Prod.Annou.(R) 1985-2006/Sep 28
         (c) 2006 The Gale Group
File   9:Business & Industry(R) Jul/1994-2006/Sep 28
         (c) 2006  The Gale Group
```

15/3,K/2 (Item 2 from file: 16)
DIALOG(R)File 16:Gale Group PROMT(R)

12648359 Supplier Number: 137910699 (USE FORMAT 7 FOR FULLTEXT)
Cook Offers First Fenestrated Endograft With CE Mark Approval For Complex Aortic Aneurysms.
Business Wire, pNA
Oct 25, 2005
Language: English Record Type: Fulltext
Document Type: Newswire; Trade
Word Count: 714

... stent-graft to treat aortic and aortoiliac aneurysms extending close to the renal and superior **mesenteric arteries** , which are then stented to **reduce** the risk of **restricting** or blocking critical **blood flow** to the kidneys and bowel. Each fenestrated device is custom-made to suit individual patients...

15/3,K/20 (Item 3 from file: 148)
DIALOG(R)File 148:Gale Group Trade & Industry DB

15375017 SUPPLIER NUMBER: 96058113 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Acute mesenteric ischemia. (Case in Point).
Schubert, Steven R.
Consultant, 42, 14, 1796(3)
Dec, 2002
ISSN: 0010-7069 LANGUAGE: English RECORD TYPE: Fulltext
WORD COUNT: 1414 LINE COUNT: 00136

... mesenteric artery causes ischemia in the small intestine and the right half of the colon. **Reduced blood flow** from the inferior **mesenteric artery** leads to ischemia of the distal transverse colon and proximal rectum. Possible sequelae range from...

15/3,K/27 (Item 10 from file: 148)
DIALOG(R)File 148:Gale Group Trade & Industry DB

07293760 SUPPLIER NUMBER: 15441934 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Management of oesophageal varices. (review article)
Bornman, P.C.; Krige, J.E.J.; Terblanche, J.
Lancet, v343, n8905, p1079(6)
April 30, 1994
ISSN: 0099-5355 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT
WORD COUNT: 5598 LINE COUNT: 00482

... not cause systemic vasoconstriction. Somatostatin acts on the smooth muscle of splanchnic vessels with a **reduction** in **splanchnic** and hepatic **blood flow** . Although the **reduction** of wedged hepatic, portal, and intravariceal pressures appears to be modest in stable cirrhotics, azygous...

15/3,K/29 (Item 12 from file: 148)
DIALOG(R)File 148:Gale Group Trade & Industry DB

06748682 SUPPLIER NUMBER: 14425718 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Octreotide infusion or emergency sclerotherapy for variceal haemorrhage.
Sung, Joseph J.Y.; Chung, S.C. Sydney; Lai Chi-Wai; Chan, Francis K.L.; Leung, Joseph W.C.; Yung Man-Yee; Kassianides, Chris; Li, Arthur K.C.
Lancet, v342, n8872, p637(5)
Sept 11, 1993
ISSN: 0099-5355 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT; ABSTRACT
WORD COUNT: 3006 LINE COUNT: 00249

... Even with the best combination - terlipressin and nitroglycerin - the results are conflicting.[3] Native somatostatin **reduces splanchnic blood flow** ,[4] and azygous **blood** flow, a measurement of collateral circulation including variceal flow that falls with an infusion of...

15/3,K/40 (Item 23 from file: 148)
DIALOG(R)File 148:Gale Group Trade & Industry DB

03939528 SUPPLIER NUMBER: 07731657 (USE FORMAT 7 OR 9 FOR FULL TEXT)
Acute mesenteric ischemia: what's new in GI ischemic disorders? (part 1)
Brandt, Lawrence J.; Dickstein, George
Consultant, v29, n6, p107(6)
June, 1989
ISSN: 0010-7069 LANGUAGE: ENGLISH RECORD TYPE: FULLTEXT
WORD COUNT: 4114 LINE COUNT: 00376

... In experimental models of acute mesenteric ischemia, tonometry has made correct and reproducible determinations of **diminished intestinal blood flow** .[24] While promising, the utility of ...Also, theoretically, the increased intraluminal pressure caused by the distention that accompanies these procedures may **decrease** the already compromised **intestinal blood flow** .

Hydrogen gas clearance. Hydrogen gas clearance is a well documented endoscopic technique used to assess...

...predicted by reflectance spectrophotometry and laser Doppler methods, displayed a linear correlation with the percentage **decreasing** in superior **mesenteric artery flow** , tonometry showed a linear **decrease** only when **arterial** occlusion was greater than 25%.

Endoscopic reflectance spectrophotometry is discussed in detail in part 2...

```
Set     Items   Description
S1     225304   BLOOD? OR ARTER? OR VASCULA? OR ENDOVASCULAR OR CIRCULATORT
S2       9330   CIRCULATORY
S3     231268   S1:S2
S4      51349   GASTRIC OR GASTRODUOD? OR DUODEN? OR MESENTER? OR  JEJUNO?
             OR JEJUN?? OR ILE?? OR ILEO? OR INTESTIN? OR SPLANCHN?
S5         67   BLOODFLOW?
S6    3007344   FLOW OR SUPPLY??? OR SUPPLI???
S7    4951221   INHIBIT? OR REDUC? OR DECREAS? OR DIMINISH? OR LESSEN? OR -
            RESTRICT? OR RETARD OR HINDER? OR LIMIT? OR CONSTRICT???
S8    3825589   PRODUC??? OR INDUC??? OR CREAT???
S9       2315   S3(5N)S4
S10    164432   S7(5N)(S3 OR S5 OR S6)
S11       378   S9(S)S10
S12    136747   S7(5N)S8
S13        30   S11(S)S12
S14      1218   S3(2N)S4
S15     95050   S7(2N)(S3 OR S5 OR S6)
S16     25088   S3(5N)S7
S17       123   S14(S)S15(S)S16
File 347:JAPIO Dec 1976-2005/Dec(Updated 060404)
         (c) 2006 JPO & JAPIO
File 350:Derwent WPIX 1963-2006/UD=200661
         (c) 2006 The Thomson Corporation
```

17/5/9 (Item 9 from file: 155)
DIALOG(R)File 155:MEDLINE(R)

21677217 PMID: 16915109

Membrane microdialysis: Evaluation of a new method to assess splanchnic tissue metabolism.

Knuesel Rafael; Takala Jukka; Brander Lukas; Haenggi Matthias; Bracht Hendrik; Porta Francesca; Jakob Stephan M

Clinic for Intensive Care Medicine, University Hospital of Bern (Inselspital), Bern, Switzerland.

Critical care medicine (United States) Oct 2006, 34 (10) p2638-45, ISSN 0090-3493--Print Journal Code: 0355501

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Process

Subfile: AIM; INDEX MEDICUS

OBJECTIVE: Measuring peritoneal lactate concentrations could be useful for detecting **splanchnic** hypoperfusion. The aims of this study were to evaluate the properties of a new membrane-based microdialyzer in vitro and to assess the ability of the dialyzer to detect a clinically relevant decrease in **splanchnic** blood flow in vivo. DESIGN: A membrane-based microdialyzer was first validated in vitro. The same device was tested afterward in a randomized, controlled animal experiment. SETTING: University experimental research laboratory. SUBJECTS: Twenty-four Landrace pigs of both genders. INTERVENTIONS: In vitro: Membrane microdialyzers were kept in warmed sodium lactate baths with lactate concentrations between 2 and 8 mmol/L for 10-120 mins, and microdialysis lactate concentrations were measured repeatedly (210 measurements). In vivo: An extracorporeal shunt with blood reservoir and roller pump was inserted between the proximal and distal abdominal aorta, and a microdialyzer was inserted intraperitoneally. In 12 animals, total **splanchnic** blood flow (measured by transit time ultrasound) was reduced by a median 43% (range, 13% to 72%) by activating the shunt; 12 animals served as controls. MEASUREMENTS AND MAIN RESULTS: In vitro: The fractional lactate recovery was 0.59 (0.32-0.83) after 60 mins and 0.82 (0.71-0.87) after 90 mins, with no further increase thereafter. At 60 and 90 mins, the fractional recovery was independent of the lactate concentration. In vivo: Abdominal blood flow reduction resulted in an increase in peritoneal microdialysis lactate concentration from 1.7 (0.3-3.8) mmol/L to 2.8 (1.3-6.2) mmol/L (p = .006). At the same time, **mesenteric** venous-arterial lactate gradient increased from 0.1 (-0.2-0.8) mmol/L to 0.3 (-0.3 -1.8) mmol/L (p = .032), and **mesenteric** venous-arterial Pco2 gradients increased from 12 (8-19) torr to 21 (11-54) torr (p = .005). CONCLUSIONS: Peritoneal membrane microdialysis provides a method for the assessment of **splanchnic ischemia** , with potential for clinical application.

Record Date Created: 20060919

17/5/15 (Item 14 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0015239652 - Drawing available
WPI ACC NO: 2005-589724/200560
XRAM Acc No: C2005-177900
XRPX Acc No: N2005-483633
Treatment of morbid obesity in patient, by reducing **gastric** blood flow , duodenal blood **flow,** mesenteric blood **flow,** jejunal blood **flow, and/or** ileal blood **flow in patient**
Patent Assignee: MURPHY T P (MURP-I)
Inventor: MURPHY T P
Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
US 20050171556	A1	20050804	US 2004770403	A	20040204	200560 B

Priority Applications (no., kind, date): US 2004770403 A 20040204

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
US 20050171556	A1	EN	9	4	

Alerting Abstract US A1
NOVELTY - Treatment of morbid obesity in a patient comprises **reducing gastric blood flow , duodenal blood** flow, **mesenteric blood** flow, **jejunal blood** flow, and/or **ileal blood** flow in the patient.
DESCRIPTION - INDEPENDENT CLAIMS are also included for:

1.an endograft (100) comprising a hollow first portion configured and arranged to be self-expanding, and a hollow second portion attached to the first portion configured and arranged to be expandable and to maintain a shape; and

2.a system comprising an endograft, and a hollow elongated sheath having a lumen and a distal end, the endograft positioned in the sheath lumen at the sheath distal end.

USE - For treating morbid obesity in a patient.
ADVANTAGE - The inventive method is safe and effective.
DESCRIPTION OF DRAWINGS - The figure schematically illustrates an endograft device.
100 Endograft device
102 First end section
104 Second end section
106 Central section
118 Lumen
Title Terms/Index Terms/Additional Words: TREAT; OBESITY; PATIENT; REDUCE; GASTRIC; BLOOD; FLOW; DUODENAL; MESENTERY

Class Codes
International Classification (Main): A61B-017/122
(Additional/Secondary): A61F-002/06
US Classification, Issued: 606108000, 623001310, 128898000, 606158000

File Segment: CPI; EngPI
DWPI Class: A96; D22; P31; P32
Manual Codes (CPI/A-M): A04-E08; A12-V03D; D09-C

17/5/18 (Item 17 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0014650549
WPI ACC NO: 2004-832568/200482
Related WPI Acc No: 2004-832551
XRAM Acc No: C2004-288994

Method for causing constriction of arterial microvasculature e.g. striated muscle microvasculature by administration of cannabinoid receptor agonist and cyclooxygenase-2 inhibitor

Patent Assignee: BOB M (BOBM-I); MOORE B M (MOOR-I); UNIV TENNESSEE RES FOUND (UYTE-N)
Inventor: MOORE B; MOORE B M

Patent Family (5 patents, 107 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	
US 20040229928	A1	20041118	US 2003436028	A	20030512	200482	B
WO 2004100867	A2	20041125	WO 2004US11222	A	20040412	200482	E
US 6916852	B2	20050712	US 2003436028	A	20030512	200546	E
EP 1626724	A2	20060222	EP 2004760806	A	20040412	200615	E
			WO 2004US11222	A	20040412		
AU 2004238205	A1	20041125	AU 2004238205	A	20040412	200638	E

Priority Applications (no., kind, date): US 2003436028 A 20030512

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
US 20040229928	A1	EN	11	6	
WO 2004100867	A2	EN			

National Designated States,Original: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
Regional Designated States,Original: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

EP 1626724	A2	EN	PCT Application WO 2004US11222 Based on OPI patent WO 2004100867	

Regional Designated States,Original: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IT LI LT LU LV MC MK NL PL PT RO SE SI SK TR

AU 2004238205	A1	EN	Based on OPI patent WO 2004100867	

Alerting Abstract US A1

NOVELTY - A method for causing constriction of arterial microvasculature involves administration of a cannabinoid receptor agonist (a1) and a COX-2 inhibitor (b1).

ACTIVITY - Hemostatic; Vasotropic; Hypertensive; Muscular-Gen.

MECHANISM OF ACTION - Cannabinoid receptor agonist (CRA); Cyclooxygenase (COX)-2 inhibitor. The effects of a CRA on cremaster arterioles, alone and in combination with a COX-2 inhibitor were studied. CRA used was Delta8-tetrahydrocannabinol (THC) and the COX-2 inhibitor used was NS-398 (N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide). The combination of THC and NS-398 produced a pronounced and prolonged constriction of cremaster arterioles of about a 45% decrease in arteriolar diameter lasting for the entire duration of the experiment of 750 seconds. Both THC alone and THC in combination with NS-398 caused an initial mild constriction of about 15% in the arterioles. At about 30 seconds post-administration, however, the diameter of the cremaster arterioles in the mice receiving only THC returned to baseline diameter. In contrast, the diameter of the

cremaster arterioles in the mice receiving both THC and NS-398 continued to decrease.

USE - For causing constriction of arterial microvasculature e.g. striated muscle microvasculature to a vertebrate subject such as mammal e.g. human; for increasing blood pressure in a subject suffering from an acute decrease in blood pressure; for treating shock e.g. hemorrhagic shock (claimed).

ADVANTAGE - The combination provides a synergistic effect when administered to a vertebrate animal and produces a pronounced, prolonged constriction of arterial microvasculature, especially in the microvasculature of striated muscle while having a lesser effect in the **splanchnic vasculature** . (b1) counters the tendency of an administered cannabinoid receptor agonist to cause dilation of arterial musculature; and controls hypotension associated with anesthetic agents. The compounds regulate tone of small blood vessels. (a1) and (b1) are administered in lower dosage.

Title Terms/Index Terms/Additional Words: METHOD; CAUSE; CONSTRICT; ARTERY; STRIATED; MUSCLE; ADMINISTER; CANNABINOID; RECEPTOR; AGONIST; INHIBIT

Class Codes
International Classification (Main): A61K, A61K-031/164, A61K-031/365, A61K-031/415
(Additional/Secondary): A61K-031/16, A61K-031/18, A61K-031/353
International Classification (+ Attributes)
IPC + Level Value Position Status Version
A61K-0031/415 A I L B 19850101
A61K-0031/52 A I F B 19850101
US Classification, Issued: 514406000, 514454000, 514473000, 514613000, 514605000, 514627000
File Segment: CPI
DWPI Class: B05
Manual Codes (CPI/A-M): B06-A03; B07-A01; B07-D04C; B07-D08; B07-E01; B10-A08; B14-F02C; B14-F08

17/5/19 (Item 18 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0014650532
WPI ACC NO: 2004-832551/
Related WPI Acc No: 2004-832568
XRAM Acc No: C2004-288977
Causing constriction of arterial microvasculature in vertebrate comprises co-administration of cannabinoid receptor agonist and cyclooxygenase-2 inhibitor
Patent Assignee: MOORE B M (MOOR-I)
Inventor: MOORE B M
Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
US 20040229850	A1	20041118	US 2003436028	A	20030512	200482 B
			US 2004822354	A	20040412	

Priority Applications (no., kind, date): US 2003436028 A 20030512; US 2004822354 A 20040412

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
US 20040229850	A1	EN	11	6	C-I-P of application US 2003436028

Alerting Abstract US A1

NOVELTY - Causing constriction of arterial microvasculature in a vertebrate comprises co-administration of a cannabinoid receptor agonist and cyclooxygenase-2 (COX-2) (preferably COX-1) inhibitor.

ACTIVITY - Hypertensive; Vasotropic; Hemostatic.

In a test, Sprague Dawley rats were injected with vehicle (200 mul) (control animals) or a binary drug solution in the same vehicle to provide a dose of tetrahydrocannabinol (THC) (12 mg/kg) and **NS-398** (RTM; N-(2-cyclohexyloxy-4-nitrophenyl)methane sulfonamide) (2 mg/kg) (test combination). The blood pressure in rats treated with vehicle continued to drop to below 20 mm Hg 40-50 minutes following the onset of stepwise bleeding. The blood pressure in rats treated with the test combination did not drop below the blood pressure (40 mm Hg) at the time of injection of the combination of COX-2 inhibitor and cannabinoid receptor agonist. The blood pressure increased following this injection and remained elevated above this blood pressure for at least 6 hours.

MECHANISM OF ACTION - None given.

USE - Used for causing constriction of arterial microvasculature (preferably striated muscle microvasculature), increasing blood pressure and for treating a subject suffering from or at risk of developing shock e.g. hemorrhagic shock (claimed).

ADVANTAGE - The method increases blood pressure when a subject is suffering from an acute decrease in blood pressure. The co-administration controls hypotension associated with anesthetic agents. The combination provides a synergistic effect and produces a pronounced, prolonged constriction of arterial microvasculature, especially in the microvasculature of striated muscle, and has a preferential effect in causing constriction of arterial vasculature of striated muscle while having a lesser effect in the **splanchnic vasculature** , which results in a shunt of blood flow away from skeletal and other striated muscle, which makes a greater volume of blood available for other organs, such as vital organs like the brain and abdominal organs. The method tones the arterial microvasculature.

Title Terms/Index Terms/Additional Words: CAUSE; CONSTRICT; ARTERY; VERTEBRATE; COMPRISE; CO; ADMINISTER; CANNABINOID; RECEPTOR; AGONIST; INHIBIT

Class Codes

International Classification (Main): A61K-031/60
(Additional/Secondary): A61K-031/365, A61K-031/415
US Classification, Issued: 514165000, 514406000, 514471000
File Segment: CPI
DWPI Class: B05
Manual Codes (CPI/A-M): B07-A01; B07-D04C; B07-D08; B07-E01; B10-A08; B10-D03; B10-E04C; B14-D05C; B14-F02A; B14-F02C; B14-L06; B14-S05

17/5/27 (Item 26 from file: 350)

DIALOG(R)File 350:Derwent WPIX

0014098996
WPI ACC NO: 2004-282770/200426
XRAM Acc No: C2004-108606

Stable, viable probiotic compositions, useful for intestinal targeting, comprise probiotic microspheres having a core (containing probiotic bacteria, a cellulosic excipient and a disintegrant) and a gastric fluid-resistant enteric coating

Patent Assignee: CANACURE CORP (CANA-N); GUERIN D (GUER-I); JOLY M (JOLY-I); MOSLEMY P (MOSL-I); PAQUETTE G D (PAQU-I); SIMMONS D L (SIMM-I)
Inventor: GUERIN D; JOLY M; MOSLEMY P; PAQUETTE G D; PAQUETTE G O; SIMMONS D L

Patent Family (4 patents, 104 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	
WO 2004022031	A2	20040318	WO 2003CA1365	A	20030908	200426	B
AU 2003266061	A1	20040329	AU 2003266061	A	20030908	200459	E
US 20050266069	A1	20051201	US 2002408348	P	20020906	200579	E
			US 2003656386	A	20030905		
AU 2003266061	A8	20051027	AU 2003266061	A	20030908	200624	E

Priority Applications (no., kind, date): US 2003656386 A 20030905; US 2002408348 P 20020906

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 2004022031	A2	EN	38	0	

National Designated States,Original: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

Regional Designated States,Original: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

AU 2003266061	A1	EN	Based on OPI patent WO 2004022031
US 20050266069	A1	EN	Related to Provisional US 2002408348
AU 2003266061	A8	EN	Based on OPI patent WO 2004022031

Alerting Abstract WO A2

NOVELTY - Viable and stable probiotic formulation (I) for intestinal targeting comprising probiotic microspheres that comprise a core (containing one or more probiotic bacteria (A), a cellulosic excipient (B), a disintegrant (C) and one or more additives (D)) and an enteric coating (E) capable of being resistant to gastric fluids, is new.

DESCRIPTION - Viable and stable probiotic formulation (I) for intestinal targeting comprises probiotic microspheres, each having a residual moisture level of less than 5% and a water activity (aw) of 0.1-0.5 and each comprising:

1.a core containing one or more probiotic bacteria (A);

2.a cellulosic excipient (B);

3.a disintegrant (C);

4.one or more additives (D); and

5.an enteric coating (E) capable of being resistant to gastric fluids.

An INDEPENDENT CLAIM is also included for the preparation of (I).

ACTIVITY - Gastrointestinal-Gen.; Immunomodulator; Antimicrobial; Hypotensive; Cytostatic.

No biological data is given.

MECHANISM OF ACTION - None given.

USE - (I) is useful for intestinal targeting (claimed) e.g. modulating immune response, improving lactose intolerance symptoms, increasing resistance to infectious **intestinal** diseases, **reducing blood** pressure and helping to prevent colon cancer.

ADVANTAGE - (I) can be prepared by cost-effective processes that are capable of entrapping and stabilizing probiotics in microspheres with minimal viability loss at the end of the entire operation. (I) provide uniform microsphere compositions within a narrow size distribution range, with low residual moisture contents and aw values that contain probiotics targeted to specific regions of the intestinal tract. Additionally, (I) are stable at room temperature for greater than 18-25 months. The bioavailability of (I) was tested by exposure to simulated gastric juice. The results showed (I) to have no reduction in viable bacteria after 1 hour exposure to the simulated gastric fluids.

Title Terms/Index Terms/Additional Words: STABILISED; VIABLE; COMPOSITION; USEFUL; INTESTINAL; COMPRISE; MICROSPHERE; CORE; CONTAIN; BACTERIA; CELLULOSIC; EXCIPIENT; DISINTEGRATE; GASTRIC; FLUID; RESISTANCE; ENTERAL; COATING

Class Codes
International Classification (Main): A23L-001/30, A61K-045/00, A61K-009/00
(Additional/Secondary): A61K-009/48, A61K-009/50
US Classification, Issued: 424451000, 424093450

File Segment: CPI
DWPI Class: A96; B04; D16
Manual Codes (CPI/A-M): A03-A05; A12-V01; B04-C02; B04-C03; B04-F10; B10-G02; B12-M11E; B14-A01; B14-F02B; B14-G03; B14-H01; D05-H04

17/5/32 (Item 31 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0013858580
WPI ACC NO: 2004-036945/200404
XRAM Acc No: C2004-014856
Obtaining fractions of acid soluble proteins of micellar casein, useful in preventing or treating diabetes type I and/or II, obesity or intestinal disorders, comprises acidifying micellar casein or enzyme-treated casein to a pH below 6
Patent Assignee: NESTEC SA (NEST)
Inventor: BOVETTO L; GREMLICH S; MACE C
Patent Family (4 patents, 99 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	
EP 1367065	A1	20031203	EP 200277076	A	20020527	200404	B
WO 2005021589	A1	20050310	WO 2003EP9669	A	20030830	200520	NCE
AU 2003270130	A1	20050316	AU 2003270130	A	20030830	200534	NCE
			WO 2003EP9669	A	20030830		
BR 200318443	A	20060801	BR 200318443	A	20030830	200655	NCE
			WO 2003EP9669	A	20030830		

Priority Applications (no., kind, date): BR 200318443 A 20030830; AU 2003270130 A 20030830; WO 2003EP9669 A 20030830; EP 200277076 A 20020527

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
EP 1367065	A1	EN	15	3	

Regional Designated States,Original: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
WO 2005021589 A1 EN
National Designated States,Original: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
Regional Designated States,Original: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
AU 2003270130 A1 EN PCT Application WO 2003EP9669
Based on OPI patent WO 2005021589
BR 200318443 A PT PCT Application WO 2003EP9669
Based on OPI patent WO 2005021589

Alerting Abstract EP A1

NOVELTY - Obtaining fractions of acid soluble proteins of micellar casein comprises acidifying micellar casein or enzyme-treated casein to a pH below 6.

DESCRIPTION - Obtaining fractions of acid soluble proteins of micellar casein comprises:

1.separating micellar or enzyme-treated casein and whey proteins;

2.acidifying micellar casein or enzyme-treated casein to a pH below 6;

3.separating acid soluble proteins from casein; and

4.separating different sub-fractions of cid soluble proteins.

INDEPENDENT CLAIMS are also included for the following:

1.a sub-fraction of acid soluble proteins from micellar casein obtainable by hydrophobic interaction chromatography and that the fraction is eluted from a hydrophobic stationary phase by a mobile phase comprising 26.4-36 or 43.2-46.4 vol.-% acetonitrile;

2.acid-soluble proteins from micellar casein for use as a medicament or preventive or therapeutic treatment of the human or animal body; and

3.a consumable product comprising any protein reaction or sub-fraction of (1) or (2).

ACTIVITY - Antidiabetic; Anorectic; Gastrointestinal-Gen.
No biological data given.
MECHANISM OF ACTION - None Given.
USE - The acid soluble proteins from the micellar casein is useful in preparing consumable products or medicaments for enhancing insulin secretion and/or proinsulin gene expression, increasing gluxagon-like-peptide-1 (GLP-1) and/or GLP-2 secretion, regulating glucose concentration in **blood** , **decreasing gastric** emptying and acid secretion, regulating appetite, decreasing food intake, increasing satiety, increasing thickness and/or surface area of the intestinal mucosa, preventing or treating diabetes type I and/or II, obesity or intestinal disorders injury or dysfunctions (all claimed).

Title Terms/Index Terms/Additional Words: OBTAIN; FRACTION; ACID; SOLUBLE; PROTEIN; MICELLAR; CASEIN; USEFUL; PREVENT; TREAT; DIABETES; TYPE; OBESITY; INTESTINAL; DISORDER; COMPRISE; ACIDIC; ENZYME; PH; BELOW

Class Codes
International Classification (Main): C07K-014/47
(Additional/Secondary): A23J-003/32, A23J-003/34, A23L-001/305, A61K-035/20, A61K-038/17, G01N-033/50
International Classification (+ Attributes)

IPC +	Level	Value	Position	Status	Version
A23J-0001/20	A	I		R	20060101
A23L-0001/305	A	I		R	20060101
A61K-0038/00	A	N		R	20060101
C07K-0014/47	A	I		R	20060101
A23J-0001/00	C	I		R	20060101
A23L-0001/305	C	I		R	20060101
A61K-0038/00	C	N		R	20060101
C07K-0014/435	C	I		R	20060101

File Segment: CPI
DWPI Class: B04; D13
Manual Codes (CPI/A-M): B04-G01; B04-G21; B04-G22; B04-N02; B04-N04; B11-B; B14-E10; B14-E12; B14-S04; D03-H01T2

17/5/56 (Item 55 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0010671867 - Drawing available
WPI ACC NO: 2001-280602/
Related WPI Acc No: 1997-289068; 1997-415091; 1999-560002
XRAM Acc No: C2001-085069
XRPX Acc No: N2001-200023
Treatment of bleeding site within gastrointestinal tract comprises

aspirating fluid from tract through elongated tube coupled to fluid recovery reservoir and treatment device

Patent Assignee: ZIMMON SCI CORP (ZIMM-N)

Inventor: ZIMMON D S

Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
US 6203520	B1	20010320	US 1995559564	A	19951116	200129 B
			US 1996597224	A	19960206	
			US 1997934248	A	19970919	
			US 1999359485	A	19990722	

Priority Applications (no., kind, date): US 1997934248 A 19970919; US 1996597224 A 19960206; US 1995559564 A 19951116; US 1999359485 A 19990722

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
US 6203520	B1	EN	17	7	C-I-P of application US 1995559564
					C-I-P of application US 1996597224
					Division of application US 1997934248
					C-I-P of patent US 5785684
					Division of patent US 5947926

Alerting Abstract US B1

NOVELTY - A patient's gastrointestinal tract is treated by aspirating fluid from the tract through an elongated tube coupled to a treatment device slidable along the outer surface of tube placed into the tract and into a fluid recovery reservoir coupled to the tube; and advancing the treatment device along the tube toward a proximal portion adjacent the bleeding site.

DESCRIPTION - Treatment of a patient's gastrointestinal tract comprises:

1. placing an elongated tube (11) coupled to a fluid recovery reservoir and a treatment device slidable along the outer surface of the tube into the patient's gastrointestinal tract;

2. aspirating fluid from the patient's gastrointestinal tract through the elongated tube and into the fluid recovery reservoir; and

3. positioning the treatment device further by engaging the treatment device with a pusher (26) slidable on the tube and advancing the treatment device along the tube toward a proximal portion adjacent the bleeding site.

USE - For treating a bleeding site within a gastrointestinal tract.

ADVANTAGE - The invention controls gastrointestinal bleeding, i.e. esophagastric variceal bleeding, while permitting simultaneous and continuous irrigation and aspiration of the stomach. The method **inhibits** aspiration of **blood** and other **gastric** contents into the lungs and treats gastrointestinal bleeding without requiring advanced medical imaging and endoscopic equipment.

DESCRIPTION OF DRAWINGS - The figure shows a perspective view of a deflated esophagastric balloon tamponade device and irrigation tube of the invention.

11 Tube
20 Obturator
25 Balloon tamponade device
26 Pusher

Title Terms/Index Terms/Additional Words: TREAT; BLEED; SITE; GASTRO; TRACT ; COMPRISE; ASPIRATE; FLUID; THROUGH; ELONGATE; TUBE; COUPLE; RECOVER; RESERVOIR; DEVICE

Class Codes
International Classification (Main): A61M-001/00
US Classification, Issued: 604028000, 604500000

File Segment: CPI; EngPI
DWPI Class: B07; P34
Manual Codes (CPI/A-M): B04-B04D5; B11-B; B11-C04; B14-E04; B14-E10; B14-K01

17/5/58 (Item 57 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0010370691
WPI ACC NO: 2000-686816/200067
XRAM Acc No: C2000-208781
XRPX Acc No: N2000-507860
Inhibiting endoleaks in a patient arising from endovascular repair of abdominal aortic aneurysms by embolizing blood vessels associated with the aneurysmal sac
Patent Assignee: MICRO THERAPEUTICS INC (MICR-N)
Inventor: CRAGG A H; DOLMATCH B; GREFF R J; RICCI C
Patent Family (5 patents, 91 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	
WO 2000056370	A1	20000928	WO 2000US7398	A	20000320	200067	B
AU 200039032	A	20001009	AU 200039032	A	20000320	200103	E
US 6303100	B1	20011016	US 1999273100	A	19990319	200164	E
EP 1163012	A1	20011219	EP 2000918170	A	20000320	200206	E
			WO 2000US7398	A	20000320		
JP 2002539853	W	20021126	JP 2000606274	A	20000320	200307	E
			WO 2000US7398	A	20000320		

Priority Applications (no., kind, date): US 1999273100 A 19990319

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 2000056370	A1	EN	37	0	
National Designated States,Original: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
Regional Designated States,Original: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW					
AU 200039032	A	EN			Based on OPI patent WO 2000056370
EP 1163012	A1	EN			PCT Application WO 2000US7398
					Based on OPI patent WO 2000056370
Regional Designated States,Original: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
JP 2002539853	W	JA	33		PCT Application WO 2000US7398
					Based on OPI patent WO 2000056370

Alerting Abstract WO A1
NOVELTY - Inhibiting endoleaks in a patient arising from endovascular repair of abdominal aortic aneurysms comprising embolizing blood vessels

associated with the aneurysmal sac including delivering through a microcatheter a biocompatible fluid composition to the vessels under solidifying conditions, is new.

DESCRIPTION - Inhibiting endoleaks in a patient arising from endovascular repair of abdominal aortic aneurysms comprising embolizing blood vessels associated with the aneurysmal sac including delivering through a microcatheter a biocompatible fluid composition to the vessels under solidifying conditions, is new. The aneurysm is repaired by catheter delivery of an endovascular prosthesis to the site of the aneurysm, thus inhibiting blood flow into the aneurysm.

An INDEPENDENT CLAIM is also included for sealing endoleaks formed after placement of an endovascular prosthesis in a mammal, comprising:

1.identifying an abdominal aortic aneurysm in a patient;

2.endovascularly repairing the aneurysm by catheter delivery of an endovascular prosthesis to the aneurysm site;

3.identifying endoleaks after placement of the prothesis; and

4.delivering through a microcatheter to the sites of endoleaks a fluid composition under conditions where it forms a coherent adhesive mass

~in situ ~, sealing the endoleaks.

USE - For inhibiting endoleaks in a patient arising from endovascular repair of abdominal aortic aneurysms.

ADVANTAGE - The invention provides a reliable endovascular method to inhibit endoleaks with endovascular graft repair of abdominal aortic aneurysms.

Title Terms/Index Terms/Additional Words: INHIBIT; PATIENT; ARISE; REPAIR; ABDOMEN; AORTA; ANEURYSM; BLOOD; VESSEL; ASSOCIATE; SAC

Class Codes
International Classification (Main): A61K-051/00, A61L-031/00
(Additional/Secondary): A61B-017/00, A61K-047/08, A61K-047/10, A61K-047/20, A61K-047/32, A61K-047/38, A61K-049/04, A61M-025/00, A61M-036/14
US Classification, Issued: 424001290, 424001730, 424001650, 424009100

File Segment: CPI; EngPI
DWPI Class: A96; B05; B07; D22; P31; P34
Manual Codes (CPI/A-M): A08-S02; A12-V; B04-C02A3; B04-C03B; B05-A01B; B05-A03B; B10-A07; B10-D03; B11-C04B; B14-F02; D09-C01

17/5/59 (Item 58 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0010034048 - Drawing available
WPI ACC NO: 2000-338844/200029
XRPX Acc No: N2000-254376
Intraluminal device for treatment of aneurysms and stenotic lesions has an expandable tubular body incorporating tabs that initially lie flat on the body or project inwards from it but which project outwards when the body is expanded
Patent Assignee: DEHDASHTIAN M (DEHD-I); EDWARDS LIFESCIENCES CORP (EDWA-N); WHITE G (WHIT-I); WHITE G H (WHIT-I)
Inventor: DEHDASHTIAN M; WHITE G H
Patent Family (7 patents, 88 countries)
Patent Application

Number	Kind	Date	Number	Kind	Date	Update	
WO 2000018322	A1	20000406	WO 1999AU832	A	19990929	200029	B
AU 199963207	A	20000417	AU 199963207	A	19990929	200035	E
EP 1123063	A1	20010816	EP 1999950401	A	19990929	200147	E
			WO 1999AU832	A	19990929		
US 20020123790	A1	20020905	US 2001966567	A	20010927	200260	NCE
JP 2002525162	W	20020813	WO 1999AU832	A	19990929	200267	E
			JP 2000571845	A	19990929		
AU 767566	B	20031113	AU 199963207	A	19990929	200381	E
AU 2004200295	A1	20040219	AU 2004200295	A	20040128	200445	E

Priority Applications (no., kind, date): AU 2004200295 A 20040128; US 2001966567 A 20010927; AU 19986243 A 19980929

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 2000018322	A1	EN	33	7	
National Designated States,Original: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW					
Regional Designated States,Original: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW					
AU 199963207	A	EN			Based on OPI patent WO 2000018322
EP 1123063	A1	EN			PCT Application WO 1999AU832
					Based on OPI patent WO 2000018322
Regional Designated States,Original: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI					
JP 2002525162	W	JA	37		PCT Application WO 1999AU832
					Based on OPI patent WO 2000018322
AU 767566	B	EN			Previously issued patent AU 9963207
					Based on OPI patent WO 2000018322
AU 2004200295	A1	EN			Division of patent AU 767566

Alerting Abstract WO A1

NOVELTY - The intraluminal device (10) comprises an expandable tubular body, capable of bridging an aneurysm or of stenting a stenotic vessel, with a number of moveable tabs attached to or integral with its surface. The aorta (11) is connected to the left and right femoral arteries (14,15), with the aortic aneurysms located between the renal arteries (16,17)and bifurcation of the aorta (18).

DESCRIPTION - When the device body is radially compressed prior to insertion, the tabs either lie flat on the body surface or project inwards from it but when the body is expanded within the target vessel, they project outwards to engage the vessel walls.

USE - As an intraluminal device for the treatment of aneurysms and stenotic lesions.

ADVANTAGE - The tabs enable the device to anchor itself within the walls of the lumen in which it is installed. Some tabs may be allowed to remain projecting inwards to provide a means for future engagement of instruments or other devices.

DESCRIPTION OF DRAWINGS - The drawings show diagrammatic longitudinal views of the device in its radially compressed and expanded states.

10 Intraluminal device
11 Aorta
14,15 Left and right femoral arteries
16,17 Renal arteries
18 Bifurcation of the aorta

Title Terms/Index Terms/Additional Words: DEVICE; TREAT; ANEURYSM; LESION;

EXPAND; TUBE; BODY; INCORPORATE; TAB; INITIAL; LIE; FLAT; PROJECT; INWARD ; OUTWARD

Class Codes
International Classification (Main): A61F-002/06, A61M-029/02
(Additional/Secondary): A61M-029/00
US Classification, Issued: 623001140, 623001360, 623001350, 623001310

File Segment: EngPI; ;
DWPI Class: P32; P34

17/5/63 (Item 62 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0009681055
WPI ACC NO: 1999-024164/199902
XRAM Acc No: C1999-007422
Use of tissue factor - to influence formation of blood vessels, e.g., in treatment of wounds
Patent Assignee: MERCKLE GMBH (MERC); MERCKLE GMBH CHEM PHARM FAB (MERC)
Inventor: NAKAGAWA K; NAWROTH P; ZHANG Y
Patent Family (15 patents, 80 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	
WO 1998051321	A1	19981119	WO 1998DE1306	A	19980508	199902	B
DE 19719652	A1	19981203	DE 19719652	A	19970509	199903	E
AU 199883315	A	19981208	AU 199883315	A	19980508	199916	E
NO 199905459	A	19991108	WO 1998DE1306	A	19980508	200008	E
			NO 19995459	A	19991108		
EP 980251	A1	20000223	EP 1998933500	A	19980508	200015	E
			WO 1998DE1306	A	19980508		
CZ 199903912	A3	20000412	WO 1998DE1306	A	19980508	200026	E
			CZ 19993912	A	19980508		
HU 200003831	A2	20010228	WO 1998DE1306	A	19980508	200121	E
			HU 20003831	A	19980508		
MX 199910214	A1	20000701	MX 199910214	A	19991108	200134	E
JP 2001527555	W	20011225	JP 1998548691	A	19980508	200204	E
			WO 1998DE1306	A	19980508		
AU 746782	B	20020502	AU 199883315	A	19980508	200238	E
EP 980251	B1	20020821	EP 1998933500	A	19980508	200262	E
			WO 1998DE1306	A	19980508		
DE 59805246	G	20020926	DE 59805246	A	19980508	200271	E
			EP 1998933500	A	19980508		
			WO 1998DE1306	A	19980508		
ES 2184299	T3	20030401	EP 1998933500	A	19980508	200328	E
CZ 293005	B6	20040114	WO 1998DE1306	A	19980508	200429	E
			CZ 19993912	A	19980508		
US 6930094	B1	20050816	WO 1998DE1278	A	19980507	200554	E
			WO 1998DE1306	A	19980508		
			US 2000423712	A	20000825		

Priority Applications (no., kind, date): WO 1998DE1306 A 19980508; DE 19719652 A 19970509; WO 1998DE1278 A 19980507

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 1998051321	A1	DE	28	3	

National Designated States,Original: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK

LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW
Regional Designated States,Original: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW

AU 199883315	A	EN		Based on OPI patent WO 1998051321
NO 199905459	A	NO		PCT Application WO 1998DE1306
EP 980251	A1	DE		PCT Application WO 1998DE1306
				Based on OPI patent WO 1998051321

Regional Designated States,Original: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE SI

CZ 199903912	A3	CS		PCT Application WO 1998DE1306
				Based on OPI patent WO 1998051321
HU 200003831	A2	HU		PCT Application WO 1998DE1306
				Based on OPI patent WO 1998051321
JP 2001527555	W	JA	22	PCT Application WO 1998DE1306
				Based on OPI patent WO 1998051321
AU 746782	B	EN		Previously issued patent AU 9883315
				Based on OPI patent WO 1998051321
EP 980251	B1	DE		PCT Application WO 1998DE1306
				Based on OPI patent WO 1998051321

Regional Designated States,Original: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE SI

DE 59805246	G	DE	Application EP 1998933500
			PCT Application WO 1998DE1306
			Based on OPI patent EP 980251
			Based on OPI patent WO 1998051321
ES 2184299	T3	ES	Application EP 1998933500
			Based on OPI patent EP 980251
CZ 293005	B6	CS	PCT Application WO 1998DE1306
			Previously issued patent CZ 9903912
			Based on OPI patent WO 1998051321
US 6930094	B1	EN	Continuation of application WO 1998DE1278
			PCT Application WO 1998DE1306
			Based on OPI patent WO 1998051321

Alerting Abstract WO A1

Use of tissue factor (I) or its fragment, to influence formation of blood vessels.

USE - (I) is a transmembrane glycoprotein which can bind the blood clotting factors VII or VIIa for activation of blood vessel formation, e.g., for replacing aged blood vessels. (I) may thus be used in wound healing to treat paraplegia, leprosy or neuropathies; in the treatment or prevention of stroke or infarct, senile dementia, arteriosclerosis, Crohn's disease or diabetic retinopathy, diabetes mellitus, vasculitis, arterial occlusions or gastric ulcers. Antibodies to (I), or a nucleic acid which has an antisense effect on the expression of (I), may be used to **inhibit** formation of **blood** vessels, especially in treatment of tumours.

Title Terms/Index Terms/Additional Words: TISSUE; FACTOR; INFLUENCE; FORMATION; BLOOD; VESSEL; TREAT; WOUND

Class Codes

International Classification (Main): A61K, A61K-038/00, A61K-038/14, A61K-038/36, A61K-045/00, A61K-048/00
(Additional/Secondary): A61K-031/70, A61K-031/711, A61K-038/19, A61K-039/395, A61P-017/02, A61P-035/00, A61P-043/00, A61P-009/00, A61P-009/14, C07K-014/745, C12N-015/09, C12N-015/12, C12N-015/74, C12N-005/02

US Classification, Issued: 514044000, 424093210, 435320100, 435325000, 435455000
File Segment: CPI
DWPI Class: B04
Manual Codes (CPI/A-M): B04-E06; B04-G02; B04-H19; B14-E08; B14-H01; B14-J01A4; B14-N16; B14-N17B; B14-S04

17/5/65 (Item 64 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0009284959 - Drawing available
WPI ACC NO: 1999-214593/
Related WPI Acc No: 1998-437102
XRPX Acc No: N1999-157943
Surgical clamp for temporarily compressing body conduit, featuring rigid base and resilient pad on clamp jaws
Patent Assignee: APPLIED MEDICAL RESOURCES CORP (MEDI-N)
Inventor: CHI-SING E; FISHBURN R; GADBERRY D L; HART C C; YAWATA H
Patent Family (3 patents, 21 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
WO 1999011179	A1	19990311	WO 1998US18296	A	19980903	199918 B
EP 1009292	A1	20000621	EP 1998945856	A	19980903	200033 E
			WO 1998US18296	A	19980903	
JP 2001514036	W	20010911	WO 1998US18296	A	19980903	200167 E
			JP 2000508291	A	19980903	

Priority Applications (no., kind, date): US 1997923211 A 19970904

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 1999011179	A1	EN	30	26	
National Designated States,Original: CA JP US					
Regional Designated States,Original: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
EP 1009292	A1	EN			PCT Application WO 1998US18296 Based on OPI patent WO 1999011179
Regional Designated States,Original: DE FR GB					
JP 2001514036	W	JA	40		PCT Application WO 1998US18296 Based on OPI patent WO 1999011179

Alerting Abstract WO A1

NOVELTY - The opposing faces of the clamp's jaws (14, 16) each carry a removable insert (43) on whose rigid base (45) is mounted a resilient pad (47). A cover (50), made of a material designed to provide good frictional contact with a body conduit, surrounds each pad's exposed face (90) and sides (92, 94). The cover may be a tight or loose fit over the pad.

USE - For temporarily compressing a body conduit, e.g. **intestine** or **blood** vessel, in order to **reduce** or occlude **flow** within it.

ADVANTAGE - As the clamp is tightened, the resilient pads deform to bring progressively more of the friction material on the inserts' sides into contact with the conduit, increasing the resistance to movement of the clamp relative to the conduit.

DESCRIPTION OF DRAWINGS - The drawing is a partial transverse cross-section through the clamp's jaws showing the deformed inserts gripping a body conduit.

14, 16 Jaws
43 Insert
45 Rigid base of insert

47 Resilient pad
50 Cover
90 Central section of cover
92, 94 Sides of cover.

Title Terms/Index Terms/Additional Words: SURGICAL; CLAMP; TEMPORARY; COMPRESS; BODY; CONDUIT; FEATURE; RIGID; BASE; RESILIENT; PAD; JAW

Class Codes
International Classification (Main): A61B-017/08, A61B-017/12

File Segment: EngPI; ;
DWPI Class: P31

17/5/69 (Item 68 from file: 350)

0008520284
WPI ACC NO: 1998-051861/
XRAM Acc No: C1998-017694
Identifying compounds useful as hypotensive or hypertensive agents - by determining their ability to relax or stimulate tension in mesenteric resistance arteries
Patent Assignee: UNIV TEXAS SYSTEM (TEXA)
Inventor: BIAN K; BUKOSKI R D
Patent Family (3 patents, 74 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	
WO 1997042951	A1	19971120	WO 1997US9097	A	19970516	199805	B
AU 199731467	A	19971205	AU 199731467	A	19970516	199814	E
US 6184254	B1	20010206	US 199618367	P	19960516	200109	E
			WO 1997US9097	A	19970516		
			US 1998180730	A	19981113		

Priority Applications (no., kind, date): US 1998180730 A 19981113; US 199618367 P 19960516

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
WO 1997042951	A1	EN	65	18	

National Designated States,Original: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU
Regional Designated States,Original: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG

AU 199731467	A	EN	Based on OPI patent WO 1997042951
US 6184254	B1	EN	Related to Provisional US 199618367 PCT Application WO 1997US9097 Based on OPI patent WO 1997042951

Alerting Abstract WO A1
Identifying a compound which modulates vascular tone via Ca2+ receptors of perivascular sensory nerves comprises: (a) contacting a mesenteric resistance artery (freed of endothelial tissue) with a compound and measuring arterial tension changes induced by the compound; (b) when tension is relieved by the compound, assuring intactness of perivascular sensory nerve Ca2+ receptor by measuring tension release of the artery by

contact with extracellular Ca2+; (c) repeating the tension assay with the compound, but after pretreatment of the mesenteric resistance artery with a Ca2+ receptor blocker, where the blocker obviates the decrease in tension caused by the compound (when it has vasodilatory activity); and (d) measuring effects of compounds (which yield positive results in steps (a) and (c)) on mesenteric resistance arteries from animals subject to chronic sensory denervation by neonatal treatment, a lack of vasorelaxation being a further positive result. Compounds which have vasomodulating activity (by stimulation or inhibition of perivascular sensory nerve Ca2+ receptors) modulate tension in the arteries of step (a), but not in those of steps (c) or (d).

USE - The process is useful for identifying compounds useful in treatment of e.g. hypertension or hypotension, angina, stroke, vasospasm, traumatic brain injury, spastic colon, intestinal cramping associated with inflammatory bowel disease, impotence, diabetic vascular injury associated with degenerative perivascular nerve function, preeclampsia and bronchospasm.

Title Terms/Index Terms/Additional Words: IDENTIFY; COMPOUND; USEFUL; HYPOTENSIVE; HYPERTENSIVE; AGENT; DETERMINE; ABILITY; RELAX; STIMULATING; TENSION; MESENTERY; RESISTANCE; ARTERY

Class Codes

International Classification (Main): A01N-033/02, A61K-031/44
(Additional/Secondary): A61K-031/135, A61K-049/00, G01N-033/53
US Classification, Issued: 514653000, 514673000, 514674000, 514920000, 514930000, 514290000, 424009200, 435003000, 435007100

File Segment: CPI
DWPI Class: B04
Manual Codes (CPI/A-M): B11-C08E1; B12-K04A

17/5/73 (Item 72 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0008023840
WPI ACC NO: 1997-117184/
XRPX Acc No: N1997-096616
Surgical treatment procedure for duodenal ulcers - reducing blood flow to stomach through left gastric artery **and right gastro-omental artery.**
Patent Assignee: KOZLOV V A (KOZL-I)
Inventor: IVANOV V V; KOZLOV V A; STOLIN A V
Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
RU 2063174	C1	19960710	RU 199313385	A	19930315	199711 B

Priority Applications (no., kind, date): RU 199313385 A 19930315

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
RU 2063174	C1	RU	5	0	

Alerting Abstract RU C1
The procedure consists of surgical intervention aimed at reducing the production of acid in the stomach and correcting the intragastric blood flow. This is achieved by isolating the left gastric artery by ligation on the proximal side of its descending branch, and the gastro-omental artery on a level with the intermediate sulcis of the stomach.
The operation is performed using an upper central laparotomy, is quickly performed, and avoids cutting into the stomach wall.
ADVANTAGE - Reduced trauma and post-operative complications, retaining stomach's innervation.

Title Terms/Index Terms/Additional Words: SURGICAL; TREAT; PROCEDURE; DUODENAL; ULCER; REDUCE; BLOOD; FLOW; STOMACH; THROUGH; LEFT; GASTRIC; ARTERY; RIGHT; GASTRO; OMENTAL

Class Codes
International Classification (Main): A61B-017/00

File Segment: EngPI; ;
DWPI Class: P31

17/5/79 (Item 78 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0007338650
WPI ACC NO: 1995-402561/
XRPX Acc No: N1995-291379
Modelling of correction of portal hypertension in animals - includes correction of portal blood flow by constriction of opening of celiac tube and cranial and caudal mesenteric arteries **by 1/3 dia.**
Patent Assignee: TERN MED INST (TEME-R)
Inventor: GERASIMYUK I E; VAIDA A R; VAIDA R I
Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
RU 2033642	C1	19950420	SU 4924876	A	19910403	199551 B

Priority Applications (no., kind, date): SU 4924876 A 19910403

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
RU 2033642	C1	RU	3	0	

Alerting Abstract RU C1

Simultaneous restriction is carried out of the openings of the arterial celiac tube and of the caudal mesenteric artery to 1/3 dia., redg. the **blood flow** through the **constricted** vessels and organs of the peritoneal cavity.

This eliminates the possibility of forming of a collateral blood flow between the system of the celiac tube and the cranial **mesenteric artery** and between the cranial and caudal **mesenteric arteries** .

USE/ADVANTAGE - Correction of portal hypertension. Reduced traumatisation of operation. Bul.11/20.4.95

Title Terms/Index Terms/Additional Words: MODEL; CORRECT; PORTAL; HYPERTENSIVE; ANIMAL; BLOOD; FLOW; CONSTRICT; OPEN; TUBE; CRANIUM; CAUDAL ; MESENTERY; ARTERY; DIAMETER

Class Codes

International Classification (Main): G09B-023/28

File Segment: EngPI; ;
DWPI Class: P85

17/5/80 (Item 79 from file: 350)

0007164829 - Drawing available
WPI ACC NO: 1995-203831/
XRAM Acc No: C1995-094396

New peptide(s) corresp. to albumin partial sequences - used as hypotensives, antagonising prostaglandin-F2alpha-induced mesenteric artery constriction

Patent Assignee: ITO HAM KK (ITOH-N)
Inventor: KASHIMOTO K; YOSHIKAWA M

Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
JP 7118292	A	19950509	JP 1993289888	A	19931026	199527 B

Priority Applications (no., kind, date): JP 1993289888 A 19931026

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
JP 7118292	A	JA	8	0	

Alerting Abstract JP A

Physiologically active peptides of formula (I) and their salts are new. H-(A)-(B)-(C)-(D)-(E)-(F)-Leu-(G)-(H)-OH (I). (A) = Arg-His-Pro-Asp, His-Pro-Asp or direct bond; (B) = Tyr or Val; (C) = Ala or Ser; (D) = Val or Ile; (E) = Val, Ser or Thr; (F) = Leu or Val; (G) = Leu or Val; (H) = Arg or Lys. Pref. (I) corresponds to 337-348, 338-348 and 341-348 peptides of human serum albumin or 337-348, 338-348 and 341-348 peptides of porcine and rat serum albumin.

USE - (I) are hypotensives which cause dilation of ilium and **mesenteric artery constricted** by PGF2alpha.

Title Terms/Index Terms/Additional Words: NEW; PEPTIDE; CORRESPOND; ALBUMIN ; SEQUENCE; HYPOTENSIVE; ANTAGONIST; INDUCE; MESENTERY; ARTERY; CONSTRICT

Class Codes
International Classification (Main): C07K-007/06
(Additional/Secondary): A61K-038/00, A61K-038/55, C07K-007/08

File Segment: CPI
DWPI Class: B04
Manual Codes (CPI/A-M): B04-C01B; B04-N02B; B14-F02B

17/5/81 (Item 80 from file: 350)

0006474011
WPI ACC NO: 1993-279373/
XRPX Acc No: N1993-214601
Large intestine lavage probe - Tubes have closed ends and outer tube bears electric heating plate with conductor for connection to electricity supply source
Patent Assignee: SENYUTOVICH R V (SENY-I)
Inventor: SENYUTOVICH R V; TSYMBALYUK V P
Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
SU 1755805	A1	19920823	SU 4626494	A	19881121	199335 B

Priority Applications (no., kind, date): SU 4626494 A 19881121

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
SU 1755805	A1	RU	2	1	

Alerting Abstract SU A1
The probe has outer (2) and inner (1) tubes with apertures in their working ends. The tubes (1,2) are made with closed ends. On the outer tube (2) there is an electric heating plate (4) equipped with a conductor for electrical connection (5) to a source of electricity supply.
USE/ADVANTAGE - As a probe for lavage of the large **intestine , reducing blood** loss in perforation of the wall of the intestine. Bul. 31/23.8.92

Title Terms/Index Terms/Additional Words: INTESTINAL; LAVAGE; PROBE; TUBE; CLOSE; END; OUTER; BEAR; ELECTRIC; HEAT; PLATE; CONDUCTOR; CONNECT; SUPPLY; SOURCE

Class Codes
International Classification (Main): A61M-009/00

File Segment: EngPI; ;
DWPI Class: P34

17/5/88 (Item 87 from file: 350)

0004325647 - Drawing available
WPI ACC NO: 1988-055586/
XRPX Acc No: N1988-042018
Oesophagoplasty left half large intestine graft vascularisation - by making auxiliary vascular arch from inferior mesentericartery segment
Patent Assignee: A MED SURGERY RES (AMSU-R)
Inventor: ANDRIANOV V A; CHERNOUSOV A F; KORCHAK A M
Patent Family (1 patents, 1 countries)

Patent			Application			
Number	Kind	Date	Number	Kind	Date	Update
SU 1324651	A	19870723	SU 4033084	A	19860304	198808 B

Priority Applications (no., kind, date): SU 4033084 A 19860304

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
SU 1324651	A	RU	4	1	

Alerting Abstract SU A

According to the proposed method, an auxiliary vascular arch is made from a segment of the inferior mesenteric artery. This is done by ligating the artery at the points above divergence (5) of the left colic artery (2) and below the divergence of the right sigmoid artery (3). The large intestine is mobilised and its vascular system is examined. If with good Riolan's arch (1) loose vascular branching is found, the main trunk of the **mesenteric artery** is prepd. A test **constriction** of the **artery** is made above divergence point (5) of the left colic artery, and below the divergence of the sigmoid **artery** . The inferior **mesenteric artery** is ligated and cut at the above level.

ADVANTAGE - **Reduces** adequate **blood** circulation when isolating a graft from the left half of the large intestine with loose branching of the vessels. Bul. 27/23.7.87

Title Terms/Index Terms/Additional Words: LEFT; HALF; INTESTINAL; GRAFT; AUXILIARY; VASCULAR; ARCH; INFERIOR; SEGMENT

Class Codes
(Additional/Secondary): A61B-017/00

File Segment: EngPI; ;
DWPI Class: P31

17/5/89 (Item 88 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0003413937
WPI ACC NO: 1985-183485/
XRAM Acc No: C1985-080221
New synthetic urotensin peptide and analogues - useful for lowering blood pressure, changing regional blood distribution, increasing e.g. ACTH secretion etc.
Patent Assignee: SALK INST BIOLOGICAL STUDIES (SALK)
Inventor: LEDERIS K P; MACCANNELL K L; RIVIER J E F
Patent Family (2 patents, 2 countries)

Patent			Application			
Number	Kind	Date	Number	Kind	Date	Update
US 4528189	A	19850709	US 1983463397	A	19830203	198530 B

CA 1247600 A 19881228 198905 E

Priority Applications (no., kind, date): US 1983463397 A 19830203

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
US 4528189	A	EN	7	0	
CA 1247600	A	EN			

Alerting Abstract US A

Synthetic polypeptides of formula (I) and their nontoxic addn. salts are new:

Y-R1-Pro-Pro-Ile-Ser-Ile-Asp-Leu -Thr-Phe-His-Leu-Leu-Arg-Asn-Met-Ile -Gln-Met-Ala-Arg-Ile-Glu-Asn-Glu-Arg -Glu-Gln-Ala-Gly-Leu-Asn-Arg-Lip-Tyr -Leu-Asp-Glu-Val-NH2 (I)

(where Y = H or acyl of up to 7C; and R1 = Asn-Asp-Asp, Asp-Asp, Asp, Ala or des-R1).

Also claimed are (i) compsns. for lowering blood pressure or for changing regional blood distribution comprising (I) as active agent, pref. for increasing intestinal blood flow and/or lowering blood pressure; and (ii) a method of elevating the secretion of ACTH and corticosteroids or beta-endorphin-like secretions employing (I).

USE - (I) are synthetic Urotensin I and fragments. (I) are useful for regulating beta-lipotropin secretion and/or for affecting mood, behavioural and gastrointestinal functions, in mesenteric ischemia (ischemic bowel syndrome, -intestinal ulceration, -colitis, -proctitis, etc), in anastomotic gut surgery (to increase blood supply to the wound and promote healing), in shock and hypertension where **decreased intestinal blood flow** is involved, and heart failure or other cardiac conditions where 'afterload' reduction is desirable, in inflammatory bowel disease etc. Doses are e.g. 0.01-200 micro g/kg.

Title Terms/Index Terms/Additional Words: NEW; SYNTHETIC; PEPTIDE; ANALOGUE ; USEFUL; LOWER; BLOOD; PRESSURE; CHANGE; REGION; DISTRIBUTE; INCREASE; ACTH; SECRETION; ADRENOCORTICAL; HORMONE; CORTICOTROPHIN

Class Codes

(Additional/Secondary): A61K-037/02, C07C-103/52, C07K-007/10
US Classification, Issued: 514012000, 530324000, 930DIG, 930010000, 930020000

File Segment: CPI
DWPI Class: B04
Manual Codes (CPI/A-M): B04-C01; B12-A07; B12-D07; B12-D10; B12-E08; B12-F01; B12-F05; B12-G01; B12-G04; B12-J01

17/5/90 (Item 89 from file: 350)

DIALOG(R)File 350:Derwent WPIX

0003167337
WPI ACC NO: 1984-265207/
XRAM Acc No: C1984-112174

Corticotropin releasing factor polypeptide(s) and analogues - useful for regulation of secretion of ACTH, lowering blood pressure, etc.

Patent Assignee: SALK INST BIOLOGICAL STUDIES (SALK); SALK INST FOR BIOLOGY (SALK)
Inventor: RIVIER J E F; SPIESS J; VALE W W

Patent Family (14 patents, 20 countries)

Patent	Application

Number	Kind	Date	Number	Kind	Date	Update
EP 122798	A	19841024	EP 1984302558	A	19840413	198443 B
AU 198426777	A	19841018				198449 E
JP 59199662	A	19841112	JP 198472606	A	19840411	198451 E
DK 198401697	A	19841015				198503 E
US 4489163	A	19841218	US 1983484931	A	19830414	198505 E
ZA 198402460	A	19840926	ZA 19842460	A	19840402	198508 E
ES 198606406	A	19861001	ES 1984531585	A	19840413	198649 E
IL 71326	A	19871130				198803 E
CA 1247602	A	19881228				198905 E
KR 199006559	B	19900913				199139 E
EP 122798	B1	19931103	EP 1984302558	A	19840413	199344 E
DE 3486238	G	19931209	DE 3486238	A	19840413	199350 E
			EP 1984302558	A	19840413	
JP 1994089034	B2	19941109	JP 198472606	A	19840411	199443 E
DK 172682	B	19990525	DK 19841697	A	19840327	199927 E

Priority Applications (no., kind, date): US 1983484931 A 19830414

Patent Details

Number	Kind	Lan	Pg	Dwg	Filing Notes
EP 122798	A	EN	31	0	
Regional Designated States,Original: AT BE CH DE FR GB IT LI LU NL SE					
US 4489163	A	EN		0	
ZA 198402460	A	EN			
IL 71326	A	EN			
CA 1247602	A	EN			
EP 122798	B1	EN	30	0	
Regional Designated States,Original: AT BE CH DE FR GB IT LI LU NL SE					
DE 3486238	G	DE			Application EP 1984302558
					Based on OPI patent EP 122798
JP 1994089034	B2	JA	10		Based on OPI patent JP 59199662
DK 172682	B	DA			Previously issued patent DK 8401697

Alerting Abstract EP A

Peptides of formula (I) and their nontoxic addn. salts are new R1-Pro-Pro-Ile-Ser-R8-R9 -Leu-R11-R12-R13-Leu-Leu Arg-R17-R18-R19-Glu-R21-R22 -R23-R24-R25-R26-R27-R28 R29-Gln-Ala-R32-R33-Asn -Arg-R36-R37-R38 -R39-R40-R41 (I) (where R1 = Glu, Gln-Glu, pGlu-Gly, Ser-Gln-Glu, D-Ser-Gln-Glu, Ser-Glu-Glu, D-Ser-Glu-Glu, Glu-Glu, D-pGlu-Gly or desR1; R8, R12, R19 and R29 each = Leu, Ile, Ala, Gly, Val, Nle, Phe, or Gln; R9 = Asp or Glu; R11 = Thr or Ser; R13 = His, Tyr or Glu; R17 = Glu or Lys; R18 = Val, Nle or Met; R21 = Met, Nva, Ile, Ala, Leu, Nle, Val, Phe or Gln; R22 = Ala, Thr, Asp or Glu; R23 = Arg, Orn, Har or Lys; R25 = Asp or Glu; R26 = Gln, Asn, or Lys; R27 = Leu, Ile, Ala, Val, Nva, Met, Nle, Phe, Asp, Asn, Gln or Glu; R28 = Ala, Arg or Lys; R29 = Gln or Glu; R32 = His, Gly, Tyr or Ala; R33 = Ser, Asn, Leu, Thr or Ala; R36 = Lys, Orn, Arg, Har or Leu; R37 = Leu or Tyr; R39 = Met or Leu; R39 = Glu or Asp; R40 = Ile, Thr, Glu, Ala, Val, Leu, Nle, Phe, Nva, Gly or Gln; R41 = Ala, Ile, Gly, Val, Leu, Nle, Phe, Gln or des R41; provided that when R38 = Leu, then R22 is Ala and/or R33 is Leu.

USES/ADVANTAGES - (I) are human or rat corticotropin releasing factor (CRF) or analogues (I) may be admin. to humans or animals for regulation or secretion of ACTH, beta-endorphin, beta-lipotropin, other prods. of the pro-opiomelanocortin gene and corticosterone and/or for lowering blood pressure and/or for affecting mood, behavioural and gastrointestinal functions and autonomic nervous system activities.

Equivalent Alerting Abstract US A

Peptide derivs. of sauvagine being corheotropin releasing factors CRF of

the formula (I) and their non-toxic salts are new.
Y-R1-Pro-Pro-Ile-Ser-R8-Asp-Leu-R11- R12-R13-Leu-Leu-Arg-
R17-R18-R19-Glu-R21-R22-R23-R24-R25 R26-R27-R28-Glu-Gln-
Ala-R32-R33-Asn-Arg-R36-Leu-R38-R39- R40-R41-NH2
(Y = 11 or 1-7C acyl; R1 = Ser-Gln-Glu, pGlu-Gly, Gln-Glu; Glu, D-Ser-Gln-Glu, Ser-Glu-Glu, D-Ser-Glu-Glu, Glu-Glu, D-pGlu-Gly or des R1, R8. R12, R19, R24 and R40 = Leu, Ile, Ala, Gly, Val, Nle, Rhe or Gln; R4 = Thr or Ser; R13 = His, Tyr or Glu; R17 = Glu or Lys; R18 = Val or Met; R21 = Met, niet(O), Ile, Ala, Leu, Gly, Nle, Val, Phe or Gln; R22 = Ala or Thr or Glu; R23 = Arg or Lys; R25 = Asp or Glu; R26 = Gln or Lys; R27 = Leu, Ile, Ala, Gly, Val, Nle, Phe, Asp, Asn, Gln, or Glu; R28 = Ala or Lys; R32 = His, Tyr or Ala; R33 = Ser, Asn, Leu, Thr or Ala; R36 = Lys or Leu, R38 = Met or Leu, R39 = Glu or Asp, R41 = Ala, Ileu; Gly, Val, Leu, Nle, Phe, Gln or des R41, provided that when R38 = Leu then R22 is Ala or non-toxic addition salt.)
USE - (I) lowers mammalian **blood** pressure, **reduces gastric** acid production, ACTH secretion modulator, beta-END-LI secretion inhibitor, corticosteroid modulus and is an agent for evaluating hypothalamic pituity adrenal function.

Title Terms/Index Terms/Additional Words: CORTICOTROPHIN; RELEASE; FACTOR; POLY; PEPTIDE; ANALOGUE; USEFUL; REGULATE; SECRETION; ACTH; LOWER; BLOOD; PRESSURE

Class Codes
International Classification (Main): C07K-014/695, C07K-007/10
(Additional/Secondary): A61K-035/30, A61K-037/00, A61K-037/02, A61K-037/24, A61K-038/16, C07C-103/52, C07K-007/38, C07K-099/00, C12N-015/00, G01N-001/00
US Classification, Issued: 436086000, 424002000, 514012000, 530324000, 930DIG, 930DIG, 930010000, 930020000, 930021000

File Segment: CPI; EPI
DWPI Class: B04; S03
Manual Codes (EPI/S-X): S03-E13
Manual Codes (CPI/A-M): B04-B04J; B04-C01; B12-E01; B12-F05; B12-G04; B12-J01; B12-K04

17/5/114 (Item 113 from file: 350)
DIALOG(R)File 350:Derwent WPIX

0001044771
WPI ACC NO: 1976-05437X/
3-Oxa-phenyl substituted prostaglandins - hypotensives, pressor agents, smooth muscle stimulants etc.
Patent Assignee: UPJOHN CO (UPJO)
Inventor: BUNDY G L
Patent Family (1 patents, 1 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update
US 3931289	A	19760106	US 1970103338	A	19701231	197603 B
			US 1971185448	A	19710930	
			US 1974459759	A	19740411	
			US 1975625179	A	19751023	
			US 1975625180	A	19751023	
			US 1975625243	A	19751023	
			US 1974459759	A	19740411	

Priority Applications (no., kind, date): US 1974459759 A 19740411

Alerting Abstract US A

Prostaglandins in the formula (I) and their lower alkanoate esters and salts when R1=H are novel:- R1 = H, (1-8C)alkyl, (3-10C)cycloalkyl, (7-12 C)aralkyl, phenyl opt. substd. by 1, 2 or 3 chloro or (1-4C)alkyl or ethyl beta-substd. by 3-Cl, 2 or 3 Br or 1,2 or 3 I; R2,R3, R4,R5 and R6=H or (1-4C)alkyl, -CnH2n-=(1-10C)alkylene with 1-5C between -CHR2- and -O-; -CtH2t=bond or (1-10C)alkylene opt. substd. by 1 or 2 F and with 1-7C between -CR3OH- and the ring; T=(1-4C)alkyl, F, Cl, CF3 or OR9; R9=H, (1-4C)alkyl or tetrahydropyranyl; s=1, 2 or 3 with the proviso no more than two T are other than alkyl; CpH2p=(1-8C)alkylene with 1,2 or 3 C atoms between -CH=CH- or C C- and -O-; Z3=-CR5R6-). (I) are hypotensives, pressor agents, smooth muscle stimulants, antilipolytics, **gastric** secretion **inhibitors** , **blood** platelet aggregation **inhibitors** , epidermal proliferation stimulants, nasal decongestants, ulcer healing accelerators, oxytocin, potentiators, atonic uterine bleeding inhibitors, labour inducers and mammalian reproductive cycle regulants.

Title Terms/Index Terms/Additional Words: OXA; PHENYL; SUBSTITUTE; HYPOTENSIVE; PRESSOR; AGENT; SMOOTH; MUSCLE; STIMULATING

Class Codes

(Additional/Secondary): C07C-005/22, C07C-069/76
US Classification, Issued: 560053000, 514822000, 514925000, 549415000, 549422000, 549454000, 554217000, 556441000, 558046000, 560118000, 560121000, 562462000, 562463000, 562470000, 562503000, 568649000

File Segment: CPI
DWPI Class: B03; B05
Manual Codes (CPI/A-M): B04-B02E; B12-A07; B12-C09; B12-E06; B12-E07; B12-E08; B12-E09; B12-F04; B12-F05; B12-G01; B12-H02; B12-H03; B12-J02; B12-K05; B12-L04